195 related articles for article (PubMed ID: 28334782)
1. Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.
Kyriakoudi S; Sargiannidou I; Kagiava A; Olympiou M; Kleopa KA
Hum Mol Genet; 2017 May; 26(9):1622-1633. PubMed ID: 28334782
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal gene therapy in mouse models expressing CMT1X mutations.
Kagiava A; Karaiskos C; Richter J; Tryfonos C; Lapathitis G; Sargiannidou I; Christodoulou C; Kleopa KA
Hum Mol Genet; 2018 Apr; 27(8):1460-1473. PubMed ID: 29462293
[TBL] [Abstract][Full Text] [Related]
3. Cellular mechanisms of connexin32 mutations associated with CNS manifestations.
Kleopa KA; Yum SW; Scherer SS
J Neurosci Res; 2002 Jun; 68(5):522-34. PubMed ID: 12111842
[TBL] [Abstract][Full Text] [Related]
4. Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease.
Olympiou M; Sargiannidou I; Markoullis K; Karaiskos C; Kagiava A; Kyriakoudi S; Abrams CK; Kleopa KA
Acta Neuropathol Commun; 2016 Sep; 4(1):95. PubMed ID: 27585976
[TBL] [Abstract][Full Text] [Related]
5. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.
Sargiannidou I; Kagiava A; Bashiardes S; Richter J; Christodoulou C; Scherer SS; Kleopa KA
Ann Neurol; 2015 Aug; 78(2):303-16. PubMed ID: 26010264
[TBL] [Abstract][Full Text] [Related]
6. Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy.
Kagiava A; Karaiskos C; Lapathitis G; Heslegrave A; Sargiannidou I; Zetterberg H; Bosch A; Kleopa KA
Mol Ther Methods Clin Dev; 2023 Sep; 30():377-393. PubMed ID: 37645436
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
Kleopa KA; Scherer SS
Neuromolecular Med; 2006; 8(1-2):107-22. PubMed ID: 16775370
[TBL] [Abstract][Full Text] [Related]
8. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.
Scherer SS; Xu YT; Messing A; Willecke K; Fischbeck KH; Jeng LJ
J Neurosci; 2005 Feb; 25(6):1550-9. PubMed ID: 15703409
[TBL] [Abstract][Full Text] [Related]
9. Aberrant trafficking of a Leu89Pro connexin32 mutant associated with X-linked dominant Charcot-Marie-Tooth disease.
Da Y; Wang W; Liu Z; Chen H; Di L; Previch L; Chen Z
Neurol Res; 2016 Oct; 38(10):897-902. PubMed ID: 27367520
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and cellular expression of two novel connexin32 mutations causing CMT1X.
Kleopa KA; Zamba-Papanicolaou E; Alevra X; Nicolaou P; Georgiou DM; Hadjisavvas A; Kyriakides T; Christodoulou K
Neurology; 2006 Feb; 66(3):396-402. PubMed ID: 16476939
[TBL] [Abstract][Full Text] [Related]
11. Connexins, gap junctions and peripheral neuropathy.
Kleopa KA; Sargiannidou I
Neurosci Lett; 2015 Jun; 596():27-32. PubMed ID: 25449862
[TBL] [Abstract][Full Text] [Related]
12. Diverse trafficking abnormalities of connexin32 mutants causing CMTX.
Yum SW; Kleopa KA; Shumas S; Scherer SS
Neurobiol Dis; 2002 Oct; 11(1):43-52. PubMed ID: 12460545
[TBL] [Abstract][Full Text] [Related]
13. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?
Kleopa KA; Abrams CK; Scherer SS
Brain Res; 2012 Dec; 1487():198-205. PubMed ID: 22771394
[TBL] [Abstract][Full Text] [Related]
14. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.
Kagiava A; Richter J; Tryfonos C; Karaiskos C; Heslegrave AJ; Sargiannidou I; Rossor AM; Zetterberg H; Reilly MM; Christodoulou C; Kleopa KA
Hum Mol Genet; 2019 Nov; 28(21):3528-3542. PubMed ID: 31411673
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling studies in regenerating nerves in a mouse model for CMT1X: uninjured Cx32-knockout peripheral nerves display expression profile of injured wild type nerves.
Freidin M; Asche-Godin S; Abrams CK
Exp Neurol; 2015 Jan; 263():339-49. PubMed ID: 25447941
[TBL] [Abstract][Full Text] [Related]
16. The effects of a dominant connexin32 mutant in myelinating Schwann cells.
Jeng LJ; Balice-Gordon RJ; Messing A; Fischbeck KH; Scherer SS
Mol Cell Neurosci; 2006 Jul; 32(3):283-98. PubMed ID: 16790356
[TBL] [Abstract][Full Text] [Related]
17. A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32.
Sargiannidou I; Kim GH; Kyriakoudi S; Eun BL; Kleopa KA
Neurogenetics; 2015 Jul; 16(3):193-200. PubMed ID: 25771809
[TBL] [Abstract][Full Text] [Related]
18. Cx32 hemichannel opening by cytosolic Ca2+ is inhibited by the R220X mutation that causes Charcot-Marie-Tooth disease.
Carrer A; Leparulo A; Crispino G; Ciubotaru CD; Marin O; Zonta F; Bortolozzi M
Hum Mol Genet; 2018 Jan; 27(1):80-94. PubMed ID: 29077882
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of connexin-32 mutants associated with X-linked dominant Charcot-Marie-Tooth disease.
Wang HL; Chang WT; Yeh TH; Wu T; Chen MS; Wu CY
Neurobiol Dis; 2004 Mar; 15(2):361-70. PubMed ID: 15006706
[TBL] [Abstract][Full Text] [Related]
20. Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects.
Sargiannidou I; Vavlitou N; Aristodemou S; Hadjisavvas A; Kyriacou K; Scherer SS; Kleopa KA
J Neurosci; 2009 Apr; 29(15):4736-49. PubMed ID: 19369543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
